Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31.28 USD | +3.97% | +4.81% | -7.25% |
05-10 | Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering | MT |
05-08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.25% | 1.4B | |
+33.04% | 709B | |
+30.77% | 595B | |
-1.74% | 367B | |
+20.21% | 334B | |
+5.94% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.08% | 171B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- RBC Capital Adjusts Pacira BioSciences Price Target to $75 From $76, Maintains Outperform Rating